Pharmaceutical titan GSK has witnessed a profit tumble owing to charges linked with the litigation over Zantac, yet has reiterated its financial forecasts, stressing stability in the company's core projections.
The firm saw its operating profit plunge 86 per cent, while earnings per share plummeted due to a substantial £1.8 billion settlement charge connected with the Zantac-related legal battles, as reported by .
Claimants who used GSK's heartburn medication Zantac have levelled accusations that it led to cancer, spawning the lawsuits in question.
READ MORE: {}
GSKs CEO Emma Walmsley commented on the decision to settle approximately 80,000 US lawsuits representing about 93 percent of the claims saying it was taken "to remove uncertainty... so we can focus forward."
In Q3, total revenues reached £8 billion, showing a 2 percent decline on an actual exchange rate measure but a 2 percent increase on a constant exchange rate footing.
GSK reported that its core operating profit and core earnings per share both rose by 5 percent.
Looking ahead, GSK is sticking to its 2024 financial outlook, forecasting turnover to climb between seven and nine percent, core operating profit to surge by 11 to 13 percent, and core earnings per share to grow by 10 to 12 percent.
Notably, vaccine sales dropped by 15 percent, however, there was an uptick in the sale of speciality medications and general pharmaceuticals by 19 percent and seven percent respectively.
Most Read
GSK explained that the decline in vaccine revenues was due to the US shifting focus to Covid vaccinations following the Advisory Committee on Immunization Practices (ACIP) recommendation for adults aged 65 and above to receive a second dose of the COVID vaccine for the year 2024-2025.
Chief executive Walmsley stated: "We have delivered another quarter of sales and core operating profit growth, and further good progress in R&D. Strong growth in speciality medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, as well as the resilience we have now built into GSK's portfolio and performance."
"Our pipeline continues to strengthen with 11 positive phase III trials reported so far this year and we are currently planning launches for 5 major new product approval opportunities next year."